Clinical TrialJul 21, 2026, 04:08 PM
Immuneering's Atebimetinib Shows Broad Antitumor Activity in Preclinical Study
AI Summary
Immuneering announced new findings in Cancer Research for its lead drug candidate, atebimetinib, highlighting its differentiated mechanism and broad preclinical antitumor activity across RAS- and RAF-mutant models. The study demonstrated that atebimetinib produced deeper, more durable tumor growth inhibition than the FDA-approved MEK inhibitor binimetinib and showed favorable tolerability. These findings reinforce atebimetinib's potential as a differentiated MEK inhibitor, with the company currently recruiting for a Phase 3 trial and planning to initiate a Phase 2 trial later this year.
Key Highlights
- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma.
- It resisted RAF-mediated bypass signaling, a key mechanism of resistance for other MEK inhibitors.
- Produced deeper, more durable tumor growth inhibition than FDA-approved binimetinib in head-to-head in vivo studies.
- Associated with favorable tolerability in preclinical models, maintaining body weight near baseline in a cancer cachexia model.
- Immuneering is recruiting patients for the global randomized Phase 3 pivotal trial MAPKeeper 301.
- Company expects to dose the first patient in a Phase 2 trial of atebimetinib plus Libtayo® in H2 2026.
Price Impact
More from IMRX